CIK 0001628171 · Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472029180
- Phone
- 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-08 | Kim Lorence H. Director | Sale 10b5-1 | −2,853 | $209.56 | $598K | 8,945 |
| 2026-09-08 | Kim Lorence H. Director | Sale 10b5-1 | −4,730 | $210.50 | $996K | 4,215 |
| 2026-09-08 | Kim Lorence H. Director | Sale 10b5-1 | −3,844 | $211.36 | $812K | 371 |
| 2026-09-08 | Kim Lorence H. Director | Sale 10b5-1 | −371 | $212.27 | $79K | 0 |
| 2026-08-31 | Kim Lorence H. Director | Sale 10b5-1 | −300 | $200.56 | $60K | 72,790 |
| 2026-08-31 | Kim Lorence H. Director | Sale 10b5-1 | −6,597 | $201.47 | $1.3M | 66,193 |
| 2026-08-31 | Kim Lorence H. Director | Sale 10b5-1 | −12,919 | $202.48 | $2.6M | 53,274 |
| 2026-08-31 | Kim Lorence H. Director | Sale 10b5-1 | −26,160 | $203.55 | $5.3M | 27,114 |
| 2026-08-31 | Kim Lorence H. Director | Sale 10b5-1 | −7,271 | $204.35 | $1.5M | 19,843 |
| 2026-08-31 | Kim Lorence H. Director | Sale 10b5-1 | −2,128 | $205.19 | $437K | 17,715 |
| 2026-08-31 | Kim Lorence H. Director | Sale 10b5-1 | −625 | $206.15 | $129K | 17,090 |
| 2026-08-21 | Cislini Jeff General Counsel | Option exercise 10b5-1 | +29,680 | $18.56 | $551K | 86,201 |
| 2026-08-21 | Cislini Jeff General Counsel | Option exercise 10b5-1 | +26,600 | $21.61 | $575K | 112,801 |
| 2026-08-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −3,400 | $207.24 | $705K | 109,401 |
| 2026-08-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −17,323 | $208.37 | $3.6M | 92,078 |
| 2026-08-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −25,817 | $209.25 | $5.4M | 66,261 |
| 2026-08-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −2,540 | $210.26 | $534K | 63,721 |
| 2026-08-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −4,500 | $211.34 | $951K | 59,221 |
| 2026-08-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −3,314 | $212.06 | $703K | 55,907 |
| 2026-08-21 | Cislini Jeff General Counsel | Option exercise · Stock Option (Right to Buy) 10b5-1 | −29,680 | 0 |
Page 5 of 18 · 352 trades